Discordance between LDL cholesterol and apolypoprotein B. Which to prefer to guide treatment?

Abstract Funding Acknowledgements Type of funding sources: None. Current cardiovascular risk guidelines recommend target values low-density lipoprotein cholesterol (LDLc) < 55 mg/dL and apolipoprotein B (apoB) 65 mg/dL. However, they don’t clarify what the attitude should be when one two targets is not achieved. Our objective was to establish prevalence LDLc ApoB discordance in a secondary prevention population our cardiac rehabilitation unit describe size particles this cohort patients. We conducted retrospective observational study including patients with previous ischemic heart disease lipid-lowering treatment followed up between February 2022 September 2022. present series 100 mean age 60.5 years (S.D. 9.7), 79% male, high factors (59% hypertension, 26% diabetes mellitus, 52% smokers). All received therapies, statins alone or combination Ezetimibe. 30 (30%) had > mg/dL, 37 (37%) reached LDL levels (LDLc mg/dL), 33 (33%) did reach any 55mg/dL mg/dL). No patient 65mg/dL. Among level achieved 55mg/dL, LDLc/ApoB ratio 1.1 0.1). The ratios stratified by are represented Figure 1 specified Table 1. conclusion that clinical practice we find group discrepancy main studies outcomes. Therefore, do know therapeutic approach take. It known these relatively apoB range correspond larger less dense particles, therefore atherogenic, it has been suggested better reflect residual than statin-treated At point, question arises is: take an their lipid controlled?